Basit öğe kaydını göster

dc.contributor.authorGultomruk, Mine
dc.contributor.authorBIBER, Necat
dc.contributor.authorToklu, Hale Z.
dc.contributor.authorBERKMAN, Zafer
dc.contributor.authorDulger, F. Gul
dc.contributor.authorSolakoglu, Seyhun
dc.contributor.authorHAKAN, Tayfun
dc.date.accessioned2021-03-02T22:58:13Z
dc.date.available2021-03-02T22:58:13Z
dc.date.issued2009
dc.identifier.citationBIBER N., Toklu H. Z. , Solakoglu S., Gultomruk M., HAKAN T., BERKMAN Z., Dulger F. G. , "Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury", BRAIN INJURY, cilt.23, sa.6, ss.577-584, 2009
dc.identifier.issn0269-9052
dc.identifier.otherav_0fb312b4-8b9b-4b1d-af3b-c60d98512e2b
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/16090
dc.identifier.urihttps://doi.org/10.1080/02699050902926317
dc.description.abstractIntroduction: Traumatic brain injury is highly associated with the over-production of reactive oxygen species. The aim of this study was to investigate the putative neuroprotective effect of montelukast, a cysteinyl-leukotriene receptor antagonist, in a rat model of traumatic brain injury (TBI). Methods: Sprague Dawley rats were subjected to TBI with a weight-drop device using 300 g-1 m weight-height impact. The groups were: control (saline), montelukast (10 mg kg -1 per day, ip), trauma and trauma + montelukast. Two days post-trauma, neurological examination scores were measured and animals were decapitated and the brain tissues were taken for the histologic and biochemical [malondialdehyde (MDA)an index for lipid peroxidation, reduced glutathione (GSH), myeloperoxidase (MPO)an index for neutrophil infiltration and Na +/K +-ATPase activity] evaluations. Brain oedema and blood-brain barrier (BBB) permeability were also evaluated. Results: The neurological examination scores mildly increased in trauma groups at 48 hours. Although the scores were decreased in the montelukast treated group, they were still significantly higher than the control. The trauma caused a significant increase in brain water content and Evans blue (EB) extravasation. Montelukast treatment reduced BBB permeability. It also decreased lipid peroxidation and MPO activity. Conclusion: The present study suggests that montelukast may have beneficial effects against TBI-induced oxidative stress of the brain.
dc.language.isoeng
dc.subjectFiziksel Tıp ve Rehabilitasyon
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectNEUROSCIENCES
dc.subjectSinirbilim ve Davranış
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectREHABİLİTASYON
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.titleCysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury
dc.typeMakale
dc.relation.journalBRAIN INJURY
dc.contributor.departmentIstanbul Haydarpasa Numune Training & Research Hospital , ,
dc.identifier.volume23
dc.identifier.issue6
dc.identifier.startpage577
dc.identifier.endpage584
dc.contributor.firstauthorID47517


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster